BioNTech SE, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on the stock and has a $122.00 price target.

Claim 55% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Tazeen Ahmad has given his Buy rating due to a combination of factors tied to BioNTech’s evolving oncology strategy and leadership transition. He views the appointment of Guido Oelkers, a seasoned executive in late-stage development and commercialization, as strengthening BioNTech’s ability to execute on its expanding oncology franchise while the company moves away from its COVID-focused phase.

At the core of his thesis is confidence in the maturing oncology pipeline, particularly pumitamig, which is now in multiple pivotal studies across several solid tumors and positioned as a key long-term growth driver. Despite reduced COVID-related revenue guidance and a slightly lower price objective of $122, he sees upcoming late-stage data readouts, the progression of ADC combination trials, and the planned T-Pam BLA in 2026 as supporting a favorable risk-reward and justifying a continued Buy stance.

According to TipRanks, Ahmad is a 4-star analyst with an average return of 5.0% and a 57.36% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Argenx Se, Incyte, and Ascendis Pharma.

In another report released today, Berenberg Bank also maintained a Buy rating on the stock with a $132.00 price target.